[
  {
    "ts": null,
    "headline": "Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal",
    "summary": "Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while there are limited data publicly available about KP-723, the deal serves as",
    "url": "https://finnhub.io/api/news?id=9424d1e9514cb7b34cf953d7d8d70d31096484fcbf2f7b02f06593c337243a2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735334706,
      "headline": "Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal",
      "id": 132181346,
      "image": "",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Leerink keeps an Outperform rating and a $60 price target on Kymera Therapeutics (KYMR) while noting that the firm sees a “positive readthrough” from the J&J’s (JNJ) in-licensing of an oral STAT6 program from Kaken Pharmaceutical. Kymera has recently started a Phase 1 for STAT6 degrader KT-621, while JNJ announced an in-licensing deal with Japan-based Kaken Pharmaceutical for small molecule STAT6 program KP-723, and while there are limited data publicly available about KP-723, the deal serves as",
      "url": "https://finnhub.io/api/news?id=9424d1e9514cb7b34cf953d7d8d70d31096484fcbf2f7b02f06593c337243a2b"
    }
  },
  {
    "ts": null,
    "headline": "Duvakitug And Teva's Growth: A Game Changer In Pharma",
    "summary": "Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.",
    "url": "https://finnhub.io/api/news?id=f932524cce0ab7e6732fb2bdfb867eccfcc2050d50d49631a3b1c7b1033d3814",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735312889,
      "headline": "Duvakitug And Teva's Growth: A Game Changer In Pharma",
      "id": 132178012,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1816401471/image_1816401471.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here to find out why TEVA is a Buy.",
      "url": "https://finnhub.io/api/news?id=f932524cce0ab7e6732fb2bdfb867eccfcc2050d50d49631a3b1c7b1033d3814"
    }
  },
  {
    "ts": null,
    "headline": "JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723",
    "summary": "Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.",
    "url": "https://finnhub.io/api/news?id=8067715c298079202eff6aaf099e12e59df362ab2fe8c0ced03780a73220bd9a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735301820,
      "headline": "JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723",
      "id": 132174877,
      "image": "https://media.zenfs.com/en/zacks.com/f3f15a36f635cd8200884e1a968d4c3d",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson announces a global licensing deal with Kaken for the latter's eczema candidate, KP-723, to further strengthen its dermatology portfolio.",
      "url": "https://finnhub.io/api/news?id=8067715c298079202eff6aaf099e12e59df362ab2fe8c0ced03780a73220bd9a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis",
    "summary": "NEW BRUNSWICK - Johnson & Johnson1 announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for...",
    "url": "https://finnhub.io/api/news?id=c7241da69da5d5fae267f5bfb004512301fd55b0d8846438fa4d87c9245ab1b7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735294335,
      "headline": "Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis",
      "id": 132174366,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "NEW BRUNSWICK - Johnson & Johnson1 announced today that it has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for...",
      "url": "https://finnhub.io/api/news?id=c7241da69da5d5fae267f5bfb004512301fd55b0d8846438fa4d87c9245ab1b7"
    }
  },
  {
    "ts": null,
    "headline": "J&J: exclusive agreement with Karen Pharmaceutical",
    "summary": "Johnson & Johnson announces that it has entered into an exclusive agreement with Kaken Pharmaceutical for the worldwide development, manufacture and commercialization of the STAT6 program for...",
    "url": "https://finnhub.io/api/news?id=79761049c9c716638097684cc8e4947e0cc969361bf1b690e5dacdacec040895",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735280591,
      "headline": "J&J: exclusive agreement with Karen Pharmaceutical",
      "id": 132172900,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that it has entered into an exclusive agreement with Kaken Pharmaceutical for the worldwide development, manufacture and commercialization of the STAT6 program for...",
      "url": "https://finnhub.io/api/news?id=79761049c9c716638097684cc8e4947e0cc969361bf1b690e5dacdacec040895"
    }
  }
]